Summary
This narrative review by Vlachostergios and Faltas examines treatment-resistant urothelial carcinoma through an evolutionary lens, as suggested by the title. The authors appear to synthesise mechanisms by which bladder cancer cells develop resistance to standard therapeutic approaches. The paper contributes to understanding how evolutionary dynamics within tumour populations inform clinical resistance patterns, though the specific mechanisms and evidence base cannot be confirmed without access to the full text.
UK applicability
The findings may inform UK oncology practice regarding urothelial carcinoma management and treatment sequencing strategies in the NHS. However, applicability depends on whether the review addresses UK-specific epidemiology, treatment protocols, or healthcare system factors.
Key measures
Treatment resistance phenotypes, evolutionary mechanisms of drug resistance, clinical outcome trajectories in urothelial carcinoma
Outcomes reported
The paper examined mechanisms of treatment resistance in urothelial carcinoma from an evolutionary perspective. It likely reviewed how cancer cells develop resistance to therapeutic interventions over time.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.